Egyptian Liver Journal (Jun 2025)

Effectiveness and safety of sofosbuvir/velpatasvir in chronic hepatitis C virus infection of Bangladeshi children

  • Salahuddin Mahmud,
  • Md. Belayet Hossain,
  • Emdadul Haque,
  • Madhabi Baidya,
  • Rafia Rashid,
  • Ahmed Rashidul Hasan,
  • Tanzila Farhana,
  • Farhana Tasneem,
  • Syed Shafi Ahmed

DOI
https://doi.org/10.1186/s43066-025-00430-2
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 8

Abstract

Read online

Abstract Background We currently advise all pediatric patients with hepatitis C virus (HCV) infection to take oral direct-acting antivirals (DAA), especially pan-genotypic medications. This study looks at how well, safely, and tolerably sofosbuvir-velpatasvir (SOF/VEL) combination therapy works for kids and teens in Bangladesh who have chronic HCV infection. Material and methods The study was prospective and carried out from January 2022 to July 2024. Three -to-18-year-olds who tested positive for HCV by polymerase chain reaction (PCR) were recruited using sequential non-probability sampling. Clinical characteristics were documented, and investigations were conducted. Every patient received SOF-VEL (150/37.5 mg for < 17 kg, 200/50 mg for 17 − < 30 kg, and 400/100 mg for ≥ 30 kg) for 12 weeks. All children were subjected to clinical and laboratory monitoring on a 4-weekly basis. Results The male–female ratio was 1.2:1, and the mean age was 11.22 ± 2.76 years. Thirty-eight patients (92.7%) had a sustained virological response (SVR), which means that their HCV PCR test was negative even 12 weeks after treatment. Three patients (7.3%) exhibited unresponsiveness or virological failure, as positive PCR results showed. After treatment, patients’ biochemical (hepatic enzymes with serum bilirubin) and clinical (jaundice, dark urine, abdominal pain, and hepatomegaly) conditions got a lot better. Almost half of the study participants said the medicine was well tolerated and had no negative effects. The most prevalent adverse effects in 6–18-year-olds were headache (23.7%), nausea with vomiting (13.2%), fatigue (7.9%), vomiting with diarrhea (33.3%), and rhinorrhea (33.3%) in the 3–5-year age group. The majority of side effects were minor and were treated symptomatically. Conclusion The SOF/VEL pan-genotypic regimen is very efficacious and well tolerated for treating chronic HCV infection in children, with no major side effects.

Keywords